Literature DB >> 8746875

The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism.

K Hashimoto1, M Nozaki, Y Inoue, M Sano, H Nakano.   

Abstract

The changes of vertebral bone mineral density (BMD; g/cm2) following oophorectomy were studied, using dual energy X-ray absorptiometry (DEXA) in 38 premenopausal and 244 oophorectomized women. Two biochemical indices of bone remodeling, urinary deoxypyridinoline (DPyr) for bone resorption and serum intact human osteocalcin (hOC) for bone formation, were also measured at the same time. The rate of bone loss in the first year after oophorectomy was 10.7%, while that in the second year was 5.7% (rapid phase), followed by a slow phase at the rate of 1.1%. The bone mass finally reached an osteoporotic level (BMD < 0.767 g/cm2) at 12 years after oophorectomy. The DPyr increased to reach a peak level in the first year, whereas the hOC increased and reached its peak level in the second year after surgery. The maximal bone loss in the first year is considered to be caused by the remarkable increase of bone resorption and the biological delay of the maximal increase in bone formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8746875     DOI: 10.1016/0378-5122(95)00940-m

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Predicting the effects of estrogen replacement therapy on lumbar bone mineral density in oophorectomized women: analysis of a 10-year longitudinal study.

Authors:  Hideaki Nagata; Masahiro Nozaki; Hitoo Nakano
Journal:  Osteoporos Int       Date:  2003-10-08       Impact factor: 4.507

2.  Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.

Authors:  Elizabeth A Hibler; James Kauderer; Mark H Greene; Gustavo C Rodriguez; David S Alberts
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

Review 3.  Current drug therapy recommendations for the treatment of endometriosis.

Authors:  A Bergqvist
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

4.  Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.

Authors:  Ingrid E Fakkert; Eveline van der Veer; Elske Marije Abma; Joop D Lefrandt; Bruce H R Wolffenbuttel; Jan C Oosterwijk; Riemer H J A Slart; Iris G Westrik; Geertruida H de Bock; Marian J E Mourits
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

5.  Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline.

Authors:  R P Hesley; K A Shepard; D K Jenkins; B L Riggs
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

Review 6.  Bone loss and the aromatase inhibitors.

Authors:  J Lester; R Coleman
Journal:  Br J Cancer       Date:  2005-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.